AARD (Aardvark Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Aardvark Therapeutics, Inc. Common Stock (AARD) is a publicly traded Healthcare sector company. As of May 21, 2026, AARD trades at $4.40 with a market cap of $95.12M and a P/E ratio of -1.33. AARD moved -1.49% today. Year to date, AARD is -67.70%; over the trailing twelve months it is -61.00%. Its 52-week range spans $3.35 to $19.58. Analyst consensus is buy with an average price target of $15.14. Rallies surfaces AARD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns AARD stock?

Rallies tracks hedge fund and 13F ownership for AARD, including fund holders, share counts, and position changes when data is available.

AARD Key Metrics

Key financial metrics for AARD
MetricValue
Price$4.40
Market Cap$95.12M
P/E Ratio-1.33
EPS$-3.21
Dividend Yield0.00%
52-Week High$19.58
52-Week Low$3.35
Volume2
Avg Volume0
Revenue (TTM)$-1.18M
Net Income$-69.87M
Gross Margin0.00%

Latest AARD News

Recent AARD Insider Trades

  • Sun Nelson bought 3.00K (~$43.20K) on Dec 11, 2025.
  • Lee Tien-Li bought 7.00K (~$101.39K) on Dec 11, 2025.
  • Lee Tien-Li bought 6.50K (~$61.82K) on Sep 15, 2025.

AARD Analyst Consensus

10 analysts cover AARD: 0 strong buy, 5 buy, 4 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $15.14.

Common questions about AARD

Who owns AARD stock?
Rallies tracks hedge fund and 13F ownership for AARD, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for AARD?
Yes. Rallies tracks hedge fund and 13F ownership data for AARD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is AARD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for AARD. It does not provide personalized investment advice.
AARD

AARD